NextCure Revenue and Competitors
Estimated Revenue & Valuation
- NextCure's estimated annual revenue is currently $14.9M per year.
- NextCure's estimated revenue per employee is $155,000
- NextCure's total funding is $310M.
- NextCure's current valuation is $154.7M. (January 2022)
Employee Data
- NextCure has 96 Employees.
- NextCure grew their employee count by -4% last year.
NextCure's People
Name | Title | Email/Phone |
---|---|---|
1 | CFO | Reveal Email/Phone |
2 | General Counsel | Reveal Email/Phone |
3 | SVP | Reveal Email/Phone |
4 | VP Program Management & Planning | Reveal Email/Phone |
5 | VP, Discovery Research | Reveal Email/Phone |
6 | VP Human Resources | Reveal Email/Phone |
7 | SVP, Clinical and Translational Development | Reveal Email/Phone |
8 | Associate Director | Reveal Email/Phone |
9 | Director, Cell Culture Development | Reveal Email/Phone |
10 | Director, Technology Transfer | Reveal Email/Phone |
NextCure Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $29.5M | 185 | 19% | N/A | N/A |
#2 | $137.1M | 483 | 2% | N/A | N/A |
What Is NextCure?
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
keywords:N/A$310M
Total Funding
96
Number of Employees
$14.9M
Revenue (est)
-4%
Employee Growth %
$154.7M
Valuation
N/A
Accelerator
NextCure News
Get NextCure alerts: Several institutional investors and hedge funds have recently made changes to their positions in NXTC. Geode Capital...
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation. NextCure. April 19, 2022 ·5 min read.
NextCure is a clinical stage biopharmaceutical company that is developing novel immunomedicines to treat cancer and other immune-related diseases.
BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Eliza ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $31.2M | 96 | 2% | N/A |
#2 | $33.6M | 104 | -1% | N/A |
#3 | $30.7M | 106 | 7% | N/A |
#4 | $26.5M | 111 | 6% | N/A |
#5 | $36M | 112 | 7% | N/A |